IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 6.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 44,560 shares of the company's stock after buying an additional 2,701 shares during the quarter. Nisa Investment Advisors LLC owned 0.05% of IDEXX Laboratories worth $24,733,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Moneta Group Investment Advisors LLC grew its holdings in IDEXX Laboratories by 121,647.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company's stock valued at $3,038,192,000 after purchasing an additional 7,441,162 shares during the last quarter. Alliancebernstein L.P. grew its holdings in IDEXX Laboratories by 6.4% during the 2nd quarter. Alliancebernstein L.P. now owns 3,592,832 shares of the company's stock valued at $1,804,428,000 after purchasing an additional 214,529 shares during the last quarter. Geode Capital Management LLC grew its holdings in IDEXX Laboratories by 1.4% during the 1st quarter. Geode Capital Management LLC now owns 1,946,339 shares of the company's stock valued at $971,569,000 after purchasing an additional 26,197 shares during the last quarter. Blair William & Co. IL grew its holdings in IDEXX Laboratories by 0.7% during the 3rd quarter. Blair William & Co. IL now owns 1,199,945 shares of the company's stock valued at $524,700,000 after purchasing an additional 7,812 shares during the last quarter. Finally, Brown Advisory Inc. grew its holdings in IDEXX Laboratories by 2.2% during the 3rd quarter. Brown Advisory Inc. now owns 1,161,124 shares of the company's stock valued at $507,725,000 after purchasing an additional 24,741 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on IDXX shares. Barclays upped their target price on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 6th. The Goldman Sachs Group increased their price objective on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a "buy" rating in a research note on Wednesday, January 17th. William Blair reiterated an "outperform" rating on shares of IDEXX Laboratories in a research note on Friday, January 5th. JPMorgan Chase & Co. increased their price objective on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an "overweight" rating in a research note on Tuesday, February 6th. Finally, Piper Sandler downgraded shares of IDEXX Laboratories from an "overweight" rating to a "neutral" rating and set a $525.00 price objective on the stock. in a research note on Tuesday, January 30th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and an average price target of $591.50.

Insider Activity at IDEXX Laboratories

In related news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the sale, the chief executive officer now owns 79,247 shares of the company's stock, valued at $45,377,624.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the firm's stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total value of $6,871,320.00. Following the completion of the transaction, the chief executive officer now owns 79,247 shares of the company's stock, valued at $45,377,624.67. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP George Fennell sold 8,198 shares of the firm's stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares of the company's stock, valued at approximately $3,851,815.44. The disclosure for this sale can be found here. Insiders sold 43,524 shares of company stock valued at $24,871,960 over the last 90 days. Insiders own 2.18% of the company's stock.

IDEXX Laboratories Stock Down 0.9 %

NASDAQ:IDXX traded down $4.84 during midday trading on Monday, reaching $514.70. 415,200 shares of the stock traded hands, compared to its average volume of 423,102. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The business has a 50-day moving average of $548.22 and a two-hundred day moving average of $506.18. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57. The stock has a market capitalization of $42.75 billion, a PE ratio of 51.11, a price-to-earnings-growth ratio of 2.85 and a beta of 1.26.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating analysts' consensus estimates of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The company had revenue of $901.60 million during the quarter, compared to analysts' expectations of $891.88 million. During the same quarter in the prior year, the company posted $2.05 earnings per share. IDEXX Laboratories's revenue for the quarter was up 8.8% compared to the same quarter last year. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.